MediciNova, Inc. 10-Q Summary
Business context and reporting period
MediciNova is a clinical-stage biopharmaceutical company developing small-molecule therapies for serious diseases with unmet medical needs. Its principal programs are MN-166 (ibudilast) for neurological disorders and MN-001 (tipelukast) for fibrotic diseases; additional programs include MN-221 and MN-029. This unaudited Form 10-Q covers the quarter and nine months ended September 30, 2016.
The company had 34,487,430 common shares outstanding as of October 21, 2016. It reported an accumulated deficit of $328.8 million and expects substantial future losses as it continues product development.
Key financial metrics
| Metric | Three months ended September 30 | Nine months ended September 30 |
|---|---|---|
| Revenue | $0 | $0 |
| Operating expenses | $2.8 million | $9.4 million |
| Net loss | $2.8 million | $9.4 million |
| Net loss per share | $0.08 | $0.29 |
| Net cash used in operating activities | Not separately provided | $5.5 million |
At September 30, 2016, cash and cash equivalents were $25.0 million, primarily held in money market funds. Working capital was $24.2 million. Total assets were $40.8 million, total liabilities were $5.0 million, and stockholders’ equity was $35.7 million.
The filing reports no debt financing. Liabilities included $1.4 million of current liabilities, a $2.0 million deferred tax liability, and $1.7 million of long-term deferred revenue. Goodwill was $9.6 million and in-process research and development was $4.8 million.
Material changes versus the prior comparable period
- Third-quarter operating expenses increased to $2.8 million from $1.6 million, primarily because of higher stock-based compensation.
- Research, development and patent expense increased to $0.9 million from $0.6 million for the quarter and to $2.9 million from $2.1 million for the nine-month period.
- General and administrative expense increased to $2.0 million from $1.0 million for the quarter and to $6.5 million from $4.0 million for the nine-month period. The nine-month increase also reflected higher professional and legal expenses.
- Third-quarter net loss increased to $2.8 million from $1.6 million; nine-month net loss increased to $9.4 million from $6.1 million.
- Cash used in operations was $5.5 million for the first nine months, compared with $5.6 million in the prior-year period.
- Financing activities provided $8.4 million, principally from the exercise of 2.1 million warrants and 172,585 stock options. No shares were sold under the company’s at-the-market agreement during the first nine months.
- Kissei converted all 220,000 Series B preferred shares into 2.2 million common shares in June 2016. Preferred shares outstanding declined to zero.
- Non-cash stock-based compensation increased to $4.0 million for the first nine months from $1.1 million in the prior-year period.
Guidance, outlook, risks and unusual items
Management stated that available capital and working capital were expected to fund operations at least through December 31, 2018, but cautioned that these resources may not support all planned research and development programs. The company may seek additional capital and strategic partnerships depending on development decisions.
Management’s strategy is to advance MN-166 through investigator-sponsored, government-funded and grant-supported trials, pursue MN-001 development in fibrotic diseases, and seek pharmaceutical partners after proof-of-concept trials. The company continues to rely on the successful development and potential commercialization of its product candidates, none of which had generated product sales during the reported periods.
- Clinical, regulatory and safety risks could delay or prevent approval of product candidates.
- The company may be unable to raise capital, generate revenue, or secure partners on acceptable terms.
- MN-166 and MN-001 are key strategic programs, increasing concentration risk.
- MediciNova owns 50% of Zhejiang Sunmy, a China joint venture intended to develop and commercialize MN-221, but no sublicense agreement had been executed and there was no assurance the joint venture could proceed.
- Development and commercialization depend substantially on third parties, including clinical research organizations, manufacturers, marketers and distributors.
- All outstanding options and warrants were excluded from diluted earnings per share because they were antidilutive. At September 30, 2016, 4.98 million options and 1.07 million warrants were outstanding.
- The filing reported no material legal proceedings, no material changes to previously disclosed risk factors, and no subsequent events requiring recognition or disclosure.
The company amended its at-the-market issuance agreement in September 2016 to add FBR Capital Markets as a sales agent. The agreement permits aggregate offerings of up to $30.0 million, subject to actual sales and market conditions.
Most important facts for investors to verify
- Whether the reported $25.0 million cash balance and management’s projected runway remain adequate for planned clinical programs.
- The timing, funding sources and results of MN-166 and MN-001 clinical development activities.
- Progress toward strategic partnerships or non-dilutive funding.
- Potential dilution from the at-the-market facility, stock options and remaining warrants.
- Whether Zhejiang Sunmy obtains the required MN-221 sublicense and advances development in China.
- The sustainability of increased stock-based compensation and general and administrative spending.
- Future revenue recognition under the $2.5 million Kissei research and development services agreement, which produced no revenue during the reported periods.